Overview

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Collaborator:
Takeda Pharmaceuticals North America, Inc.
Treatments:
Glyburide
Pioglitazone